BCAB Stock Summary and Trading Ideas (Bioatla | NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Bioatla trades on the NASDAQ stock market under the symbol BCAB.

As of January 27, 2025, BCAB stock price declined to $0.49 with 336,796 million shares trading.

BCAB has a beta of 4.40, meaning it tends to be more sensitive to market movements. BCAB has a correlation of 0.16 to the broad based SPY ETF.

BCAB has a market cap of $28.48 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCAB traded as high as $12.15 and as low as $.45.

The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VTI, VXF, IWC, FORH.

BCAB has underperformed the market in the last year with a price return of -76.2% while the SPY ETF gained +24.4%. BCAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -75.3% and -1.6%, respectively, while the SPY returned +3.9% and +3.1%, respectively.

BCAB support price is $.47 and resistance is $.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.